ArticleThorax2023
Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study.
Article in Thorax, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Psychosocial experience of living with severe and uncontrolled asthma as a young adult: a qualitative synthesis.BMJ open respiratory research · 2025Pooled it
- Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAIN.Advances in therapy · 2026Trial
- Biologic effectiveness increases with earlier biologic initiation after severe asthma onset.The journal of allergy and clinical immunology. Global · 2026Article
- Effect of once-daily ICS/LAMA/LABA triple therapy versus ICS/LABA on respiratory symptoms (E-RS: Asthma): Analysis of the phase IIIA CAPTAIN trial.The journal of allergy and clinical immunology. Global · 2026Article
- Baseline Characteristics of Patients with Asthma Initiating Dupilumab in a Real-World Setting: The REVEAL Registry.Advances in therapy · 2026Observational
- Review
- High degree of remission in pediatric severe asthma patients treated with biologics in a real-world setting.The World Allergy Organization journal · 2026Article
- Global, regional, and national burden of chronic obstructive pulmonary disease and asthma from 1990 to present: risk attributions and projections to 2050.Internal and emergency medicine · 2026Article
- Characteristics and management of asthma from the China Asthma Data Registry Project.ERJ open research · 2026Article
- Adverse outcomes in young adults with severe asthma: results from the UK Severe Asthma Registry.ERJ open research · 2026Article
- Association between the C-reactive protein-triglyceride-glucose index and asthma risk: evidence from the NHANES cohort and validation in the CHNS cohort.Clinics (Sao Paulo, Brazil) · 2026Article
- Review
- A Pragmatic RCT of FF/UMEC/VI in Patients with Uncontrolled Asthma: PERFORM Protocol.Pulmonary therapy · 2026Article
- Longitudinal observation of severe asthma comorbidities and oral corticosteroids use from SANI and ISAR registries.The World Allergy Organization journal · 2026Article
- Clinical Remission and Its Determinants in Adult Severe Asthma Patients Receiving Biologic Therapy: A Retrospective Analysis.Journal of clinical medicine · 2026Article
- Associations Between Social Determinants of Health and Adherence to Biologic Therapies in Patients with Severe Asthma: Real-World Evidence from a Large US Claims Analysis.Journal of asthma and allergy · 2026Article
- Chronic respiratory morbidity and wheeze after preterm birth: a narrative review.Frontiers in pediatrics · 2026Review
- Clinical and pathophysiological roles of lower lobe-dominant mucus plugs on computed tomography in patients with asthma with and without bronchiectasis.The journal of allergy and clinical immunology. Global · 2025Article
- Extended antibiotic exposure and exacerbations, mortality, and healthcare costs in asthma.Scientific reports · 2025Article
- Real-World Effectiveness of Omalizumab Treatment in Adult Asthma Patients.Yonsei medical journal · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleProgressive lung function (LF) decline in patients with asthma contributes to worse outcomes. Asthma exacerbations are thought to contribute to this decline; however, evidence is limited with mixed results.
methodsThis historical cohort study of a broad asthma patient population in the Optimum Patient Care Research Database, examined asthma patients with 3+eligible post-18th birthday peak expiratory flow rate (PEF) records (primary analysis) or records of forced expiratory flow in 1 s (FEV
resultsWe studied 1 09 182 patients with follow-up ranging from 5 to 50 years, of which 75 280 had data for all variables included in the adjusted analyses. For each additional exacerbation, an estimated additional -1.34 L/min PEF per year (95% CI -1.23 to -1.50) were lost. Patients with AERs >2/year and aged 18-24 years at baseline lost an additional -5.95 L/min PEF/year (95% CI -8.63 to -3.28) compared with those with AER 0. These differences in the rate of LF decline between AER groups became progressively smaller as age at baseline increased. The results using FEV
conclusionTo our knowledge, this study is the largest nationwide cohort of its kind and demonstrates that asthma exacerbations are associated with faster LF decline. This was more prominent in younger patients but was evident in older patients when it was related to lower starting LF, suggesting a persistent deteriorating phenotype that develops in adulthood over time. Earlier intervention with appropriate management in younger patients with asthma could be of value to prevent excessive LF decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.